Under Trump's tariff threats, a new "landscape" in the USA: stockpiling medicine!
According to several Company Executives in the Pharmaceutical industry and Logistics companies, due to concerns that the reciprocal tariffs announced by President Trump on April 2 may involve Pharmaceutical products from Europe, some Pharmaceutical companies are taking unusual measures to transport more drugs to the USA via Air Transportation; Two Pharmaceutical companies headquartered in Europe stated to the media this week that they have transported as many Pharmaceutical products to the USA as possible in recent weeks, and they have also learned that other Pharmaceutical companies are taking similar actions.
The 'High Tide' of 2024 Is Over: Buy the Dip & 'Be Tactical'
High Tide First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Earnings Call Summary | High Tide(HITI.US) Q1 2025 Earnings Conference
Express News | High Tide Shares Are Trading Lower After the Company Reported a Q1 Gaap EPS Miss
High Tide Inc. Achieves Record Revenue in Q1 2025 Amid Strategic Expansion
High Tide Stock Slides On Q1 Earnings, Company Says Canadian Cannabis Business 'Continues To Get Stronger Every Day'
High Tide Down 5% After Hours as Its Fiscal Q1 Loss Widens; Points To "Purposeful Shift" In Strategy
High Tide Inc. (HITI) Reports Q1 Loss, Tops Revenue Estimates
High Tide Reiterates Long-Term Goal to Reach 300 Locations Across Canada >HITI.V
High Tide Objective Remains to Add Another 20-30 Canna Cabana Locations 2025
High Tide 1Q Same-Store Sales Increased 5%
High Tide Reports Q1 EPS (C$0.03) Vs. C$0.00 Last Year
Express News | High Tide Q1 2025 GAAP EPS C$(0.03), Sales C$142.461M
High Tide 1Q Loss/Shr C$0.03 >HITI.V
High Tide 1Q Rev C$142.5M >HITI.V
High Tide 1Q Loss C$2.69M >HITI.V
Press Release: High Tide Reports First Quarter 2025 Financial Results Featuring Record Revenue of $142.5 Million
Here Are the Major Earnings After the Close Today
Roth MKM Maintains High Tide(HITI.US) With Buy Rating, Maintains Target Price $4.5